Related references
Note: Only part of the references are listed.Intravenous prostacyclin-analogue therapy in pulmonary arterial hypertension - A review of the past, present and future
Beate Stubbe et al.
RESPIRATORY MEDICINE (2021)
Risk stratification and medical therapy of pulmonary arterial hypertension
Nazzareno Galie et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience
Olivier Sitbon et al.
EUROPEAN RESPIRATORY REVIEW (2017)
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)
Nazzareno Galie et al.
EUROPEAN HEART JOURNAL (2016)
Comparative Safety and Tolerability of Prostacyclins in Pulmonary Hypertension
Caroline O'Connell et al.
DRUG SAFETY (2016)
Quality of Life, Safety and Efficacy Profile of Thermostable Flolan in Pulmonary Arterial Hypertension
Steeve Provencher et al.
PLOS ONE (2015)
Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study
Kelly M. Chin et al.
AMERICAN HEART JOURNAL (2014)
EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension
Olivier Sitbon et al.
AMERICAN HEART JOURNAL (2014)
Epoprostenol (Veletri (R), Caripul (R)): A Review of Its Use in Patients with Pulmonary Arterial Hypertension
Sarah L. Greig et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2014)
Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study
Olivier Sitbon et al.
EUROPEAN RESPIRATORY JOURNAL (2014)
Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: Data from the French pulmonary hypertension registry
Emmanuel Bergot et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2014)
Evaluation of a New Formulation of Epoprostenol Sodium in Japanese Patients with Pulmonary Arterial Hypertension (EPITOME4)
Yuichi Tamura et al.
ADVANCES IN THERAPY (2013)
Health related quality of life in adults in Germany. Results of the German Health Interview and Examination Survey for Adults (DEGS1)
U. Ellert et al.
BUNDESGESUNDHEITSBLATT-GESUNDHEITSFORSCHUNG-GESUNDHEITSSCHUTZ (2013)
A new epoprostenol formulation for the treatment of pulmonary arterial hypertension
Amaris Fuentes et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2012)
Stability and microbiological properties of a new formulation of epoprostenol sodium when reconstituted and diluted
Olivier Lambert et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2012)
Prostacyclin therapy for pulmonary arterial hypertension: New directions
M Gomberg-Maitland et al.
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE (2005)
Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease -: A randomized, controlled trial
DB Badesch et al.
ANNALS OF INTERNAL MEDICINE (2000)
Share Paper
